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Abstract
Aims/hypothesis Hyperinsulinaemia is associated with obesi-
ty but its causal role in the onset of obesity remains contro-
versial. In this study, we tested the hypothesis that transient
attenuation of diet-induced insulin hypersecretion in young
mice can provide sustained protection against obesity
throughout adult life.
Methods Using ‘genetically humanised’ mice lacking both
alleles of rodent-specific Ins1, we compared mice heterozy-
gous for the ancestral insulin gene Ins2 with Ins2+/+ controls.
Female Ins1−/−:Ins2+/− and Ins1−/−:Ins2+/+ littermates were fed
chow or high-fat diet (HFD). Insulin secretion, metabolic
health variables and body mass/composition were tracked
for over 1 year. We examined islet function and adipose tran-
script levels of adipogenic, lipogenic and lipolytic genes at
two time points.
Results In control Ins1−/−:Ins2+/+ mice, HFD resulted in ele-
vated fasting and glucose-stimulated insulin secretion be-
tween 8 weeks and 27 weeks of age. Hyperinsulinaemia was
reduced by nearly 50% in Ins1−/−:Ins2+/− mice during this
period, without lasting adverse effects on glucose homeosta-
sis. This corresponded with attenuated weight gain and adi-
posity. White adipose tissue from Ins1−/−:Ins2+/− mice had
fewer large lipid droplets, although transcriptional changes
were not detected. Importantly, Ins1−/−:Ins2+/−mice remained
lighter than Ins1−/−:Ins2+/+ littermates despite reaching an
equivalent degree of hyperinsulinaemia on HFD by 52 weeks.
Conclusions/interpretation These data demonstrate that
attenuation of hyperinsulinaemia in young, growing female
mice provides a long-lasting protection against obesity. This
protection persists despite a late-onset emergence of
hyperinsulinaemia in HFD-fed Ins1−/−:Ins2+/− mice. Given
the evolutionary conserved roles of insulin, it is possible that
suppressing hyperinsulinaemia early in life may have far-
reaching consequences on obesity in full-grown adult
humans.
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Abbreviations
BAT Brown adipose tissue
CD Chow diet
DEXA Dual-energy x-ray absorptiometry
GIP Glucose-dependent insulinotropic polypeptide
HFD High-fat diet
WAT White adipose tissue
Introduction
Over 40 million children younger than 5 years of age were
overweight worldwide in 2011 [1], and being overweight or
obese during childhood and adolescence is a predictor of adult
obesity [2, 3]. Obesity is a risk factor for type 2 diabetes,
coronary heart disease, hypertension, atherosclerosis and
some cancers; many of these diseases are traditionally associ-
ated with adulthood but are occurring with increasing
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prevalence in youth [4]. Hyperinsulinaemia and insulin resis-
tance are two characteristics of the obese state that have been
proposed to contribute to its detrimental effects on health [5,
6]. Circulating insulin levels are intimately related to systemic
insulin responsiveness, and the most widely held paradigm
posits that obesity leads to insulin resistance, causing a com-
pensatory rise in insulin to prevent hyperglycaemia [5, 6].
However, clinical and experimental evidence suggests that
hyperinsulinaemia can precede and promote obesity [7–11].
Drugs that suppress insulin secretion in hyperinsulinaemic
obese rodents or humans lead to weight loss [12–14]. Obese
individuals with the highest insulin levels respond best to diets
that reduce postprandial glycaemia and insulinaemia whereas
those with less-elevated insulin show equivalent weight loss
on low-fat diets [15, 16]. Insulin is known to suppress lipoly-
sis and stimulate lipogenesis in white adipose tissue (WAT)
[17], and mouse models with reduced adipose tissue insulin
signalling are protected against obesity [18, 19].
We exploited the existence of two rodent insulin genes
(Ins1 and Ins2) to genetically manipulate endogenous insulin
production. Recent work in our laboratory demonstrated that
continuous suppression of fasting hyperinsulinaemia through
reducing Ins1 dosage (in an Ins2 null background) prevented
diet-induced obesity in male mice [11]. However, Ins1 is a
rodent-specific gene, and there are differences in promoter
elements and expression patterns between Ins1 and Ins2 [11,
20–23]. As it is unclear whether Ins1 and Ins2 have distinct
roles, we felt it important to examine the effects of reduced
Ins2 dosage in the development of high-fat diet (HFD)-in-
duced obesity.
Certain life stages are important for adipocyte hyperplasia
and hypertrophy but the mechanisms controlling WAT expan-
sion, and their timing, remain to be fully elucidated [24].
White adipocyte cell number is thought to stabilise towards
the end of adolescence in non-obese humans and rodents [24],
which suggests that conditions during this programming peri-
od could influence future adiposity. Indeed, adolescence has
been identified as a key life stage for the development of
obesity in humans, since the presence or onset of obesity dur-
ing adolescence is associated with increased incidence of its
associated morbidities in adults [25]. In our previous study,
the Ins1+/−:Ins2−/− genetic manipulation resulted in life-
long prevention of hyperinsulinaemia [11], which pre-
cluded an assessment of whether anti-obesity effects
would persist without sustained repression of insulin. In
the present study, we found that high-fat-fed female
Ins1−/−:Ins2+/− mice had reduced insulin secretion at a
young age but by 1 year they had reached a degree of
hyperinsulinaemia equivalent to that of high-fat-fed
Ins1−/−:Ins2+/+ littermates. This provided a unique model
with which to test the hypothesis that the reduction of
insulin secretion in young, growing mice can provide
long-term protection against diet-induced obesity.
Methods
Experimental animals All animal procedures were approved
by the University of British Columbia Animal Care
Committee, following Canadian Council for Animal Care
guidelines. The Ins1-null and Ins2-null alleles were generated
by Jami and colleagues [26]. Mice had mixed genetic back-
ground (predominately C57BL/6 and 129 strains).
Ins1−/−:Ins2+/+ and Ins1−/−:Ins2+/− female mice from each lit-
ter were weaned (at 3–4 weeks) and distributed (with
matching body weights) between two diet assignments: a
moderate-energy chow diet (CD) (25% fat content; LabDiet
5LJ5; PMI Nutrition International, St. Louis, MO, USA) or a
high-energy HFD (58% fat content; Research Diets D12330;
Research Diets, New Brunswick, NJ, USA) [11] provided ad
libitum, except during fasting periods (Fig. 1a). Mice were
housed under specific pathogen-free conditions at 21°C, on
a 12 h light–dark cycle. We considered in our studies whether
the dam or sire of individual mice had the disrupted Ins2
allele, to control for possible parental imprinting [27, 28],
but as no obvious parental effects were observed, we com-
bined ‘parental groups’. Experimenters were blind to mouse
genotype, diet (where possible), and parental group while
performing and analysing each experiment.
Glucose homeostasis and plasma analytesMice were fasted
for 4 h during the light period to ensure a postprandial state for
blood sampling. Fasting and glucose-stimulated (2 g/kg) insu-
lin secretion was assessed, as well as blood glucose response
to intraperitoneal injection of glucose (2 g/kg) or insulin ana-
logue (0.75 U/kg of Humalog; Eli Lilly, Indianapolis, IN,
USA). Plasma insulin was measured with a mouse insulin
ELISA (Alpco Diagnostics, Salem, NH, USA) and
C-peptide was measured in a subset of 27-week-old mice with
a mouse C-peptide ELISA (Alpco Diagnostics). In plasma
from 40-week-old mice, we measured total cholesterol
(Cholesterol E kit; Wako Chemicals, Richmond, VA, USA),
triacylglycerols (Serum Triacylglycerol kit; Sigma-Aldrich, St
Louis, MO, USA) and NEFA levels (NEFA-HR(2) kit; Wako
Chemicals), as well as leptin, resistin, interleukin 6, glucose-
dependent insulinotropic polypeptide (GIP), peptide YY and
glucagon, using a mouse magnetic bead panel assay utilising
Luminex technology (Millipore, St Charles, MO, USA).
Body composition and whole body metabolism A subset of
pups was weighed prior to weaning. After weaning, all mice
were weighed weekly. Body composition was assessed using
dual-energy x-ray absorptiometry (DEXA) (Lunar PIXImus
densitometer; GE Medical Systems LUNAR, Madison, WI,
USA). A subset of 17-week-old mice on HFD was evaluated
in PhenoMaster metabolic cages (TSE Systems, Chesterfield,
MO, USA), as described elsewhere [29]. Before data collec-
tion, mice were individually housed for at least 1 week and
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were allowed to become acclimated to the PhenoMaster cage
environment for at least 4 days. Data were averaged from
48–84 h of continual acquisition.
Murine INSULIN2 treatment A cohort of mice were put on
HFD at 15 weeks and subcutaneously implanted at 17 weeks
with mini osmotic pumps (Alzet 2004; DURECT, Cupertino,
CA, USA) designed to release murine INSULIN2 peptide
(0.1 U/day; generously provided by Novo Nordisk,
Bagsvaerd, Denmark) or vehicle for 28 days.
Tissue analyses Tissues were dissected from mice 4 h after
fasting. Mice were from the 50-week-old HFD-fed mini os-
motic pump group and 25-week-old CD or HFD groups. Islets
were isolated as described [30], with minor modifications, and
cultured at 37°C and 5% CO2 for at least 16 h in RPMI-1640
medium (Invitrogen, Burlington, ON, Canada) supplemented
with 11 mmol/l glucose, 100 U/ml penicillin, 100 μg/ml strep-
tomycin and FBS (10% vol./vol.). Islet perifusions were per-
formed as described [31] using 150 size-matched islets per
group. Insulin content was measured by ELISA from ten islets
per mouse that were lysed at −20°C using 0.02 mol/l HCl in
70% ethanol and sonicated for 30 s.
Other tissues were weighed and flash-frozen in liquid ni-
trogen before being stored at −80°C, except for half of the
gonadal WAT depot, which was fixed in 4% paraformalde-
hyde, embedded in paraffin and cut into 5 μm-thick sections
that were stained for perilipin (antibody 9349S; Cell Signaling
Technology, Danvers, MA, USA) using an Alexa fluor 488-
conjugated secondary antibody (Life Technologies,
Burlington, ON, Canada) and DAPI. Images with identical
exposure times were taken with a Zeiss 200 M inverted
Fig. 1 Transiently attenuated
HFD-induced hyperinsulinaemia
in Ins1−/−:Ins2+/− mice. (a)
Experimental design of
Ins1−/−:Ins2+/+ and Ins1−/−:Ins2+/−
littermates fed CD or HFD. (b, c)
Islet Ins2 mRNA is corrected
against β-actin mRNA and
normalised to CD-fed
Ins1−/−:Ins2+/+ mice at 25 weeks
(n=3–5) (b), or HFD-fed
Ins1−/−:Ins2+/+ mice at 50 weeks
(n=3) (c). (d, e) Insulin content in
islets from mice at 25 (d) and
50 weeks (e). (f–h) At 25 (f, g)
and 50 weeks (h), insulin
secretion by 150 islets perifused
with basal 3 mmol/l glucose
followed by stimulatory
15 mmol/l glucose (Glu) or
30 mmol/l KCl, with AUC
(insets; y-axis units, pmol/l×min)
depicted, including phases I/II of
glucose stimulation (n=3). (i, j)
Fasted insulin (n=17–21) (i) and
C-peptide (n=5–6) (j) at
27 weeks is from in vivo
sampling. Dark blue, CD-fed
Ins1−/−:Ins2+/+ mice; dark purple,
HFD-fed Ins1−/−:Ins2+/+ mice;
light blue, CD-fed Ins1−/−:Ins2+/−
mice; light purple, HFD-fed
Ins1−/−:Ins2+/− mice. Data are
means±SEM. *p≤0.05, CD vs
HFD; †p≤0.05, Ins1−/−:Ins2+/+ vs
Ins1−/−:Ins2+/−
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microscope (Carl Zeiss, Oberkochen, Germany) and lipid
droplet areas were determined using CellProfiler 2.1.0
(http://www.cellprofiler.org/) [32].
For real-time PCR, total RNA was extracted from islets
using the Qiagen RNeasy Mini kit (Qiagen, Mississauga,
ON, Canada), and from adipose tissue using acid guanidinium
thiocyanate–phenol–chloroform extraction with TRIzol
(Invitrogen) followed by Qiagen RNeasy Mini columns
[33]. cDNA was generated using a qScript cDNA synthesis
kit (Quanta Biosciences, Gaithersburg, MD, USA). Reactions
were performed on default parameters of a StepOnePlus real-
time PCR system (Applied Biosystems, Foster City, CA,
USA), using TaqMan Fast Universal PCR or Fast SYBR
Green Master Mixes (Applied Biosystems). See electronic
supplementary material [ESM] Table 1 for primer details.
Values were normalised using the 2−ΔCt method.
Statistical analyses Statistical analyses were performed with
SPSS 15.0 software and a criticalα-level of p≤0.05. Two-way
ANOVA models were used to assess factors of genotype and
diet and a significant interaction led to one-way ANOVAs
comparing HFD-fed Ins1− /−:Ins2+/+ mice, CD-fed
Ins1−/−:Ins2+/+ mice, HFD-fed Ins1−/−:Ins2+/− mice and CD-
fed Ins1−/−:Ins2+/− mice, with Bonferroni corrections applied.
ANCOVAwas used to test energy expenditure with covariates
of lean and fat mass. One-way ANOVAs or two-tailed t tests
were used to analyse tissue data from the 50-week time point.
Results
Attenuated hyperinsulinaemia in young HFD-fed
Ins1−/−:Ins2+/−miceTo characterise this novel model, we first
examined the effect of reduced Ins2 gene dosage on insulin
mRNA, protein and secretion. Islets from 25-week-old
Ins1−/−:Ins2+/− mice predictably expressed significantly less
Ins2 than islets from the Ins1−/−:Ins2+/+ mice, although this
difference was less marked in islets from HFD-fed mice at
50 weeks (Fig. 1b, c). No differences were observed in
Pdx1, Hnf1a, Slc2a2 or Gck expression at 50 weeks (data
not shown). Insulin protein content was also reduced by
∼50% in Ins1−/−:Ins2+/− islets compared with Ins1−/−:Ins2+/+
islets, at 25 weeks (Fig. 1d, e). Insulin secretion was modestly,
but consistently, lower in islets isolated from Ins1−/−:Ins2+/−
mice, with a significant reduction in first-phase response to
stimulatory glucose in chow-fed mice (Fig. 1f–h).
Collectively, these data demonstrate that reduced Ins2 dosage
resulted in lower insulin production, although there is poten-
tial for age-dependent compensation with HFD-feeding.
Reduced fasting insulin was detected in Ins1−/−:Ins2+/−
mice at 8 weeks, compared with Ins1−/−:Ins2+/+ mice
(Fig. 1i). Statistically significant HFD-induced fasting
hyperinsulinaemia was observed in Ins1−/−:Ins2+/+ mice by
27 weeks and insulin levels remained elevated at 1 year
(Fig. 1i). Importantly, Ins1−/−:Ins2+/− mice were protected
against HFD-induced fasting hyperinsulinaemia until at least
27 weeks (Fig. 1i). Ins1−/−:Ins2+/− mice were unable to in-
crease fasting C-peptide in response to HFD at this age,
confirming that reduced basal insulin secretion, rather than
increased insulin clearance, accounted for these differences
(Fig. 1j). At all measured time points, HFD led to higher
glucose-stimulated insulin secretion than CD, but at 8 and
15 weeks, glucose-stimulated insulin secretion was lower in
Ins1−/−:Ins2+/− mice than in Ins1−/−:Ins2+/+ littermates
(Fig. 2a). However, in this mouse model, suppression of insu-
lin secretion was not sustained since by 1 year of age
Ins1−/−:Ins2+/− female mice had equivalently high fasting
and glucose-stimulated insulin levels when compared with
the Ins1−/−:Ins2+/+ mice on HFD (Figs 1i, 2a).
Longitudinal analysis of glucose homeostasisWe found that
reduced Ins2 dosage only had minor effects on glucose ho-
meostasis (Fig. 2b–d). At 6 weeks, Ins1−/−:Ins2+/− mice had
slightly impaired glucose tolerance compared with
Ins1−/−:Ins2+/+ littermates (Fig. 2b). As marginally elevated
fasting glucose levels were observed in 5- to 8-week-old
Ins1−/−:Ins2+/− mice (Fig. 2d), insulin secretion may not be
completely sufficient for normal glycaemic control in very
young Ins1−/−:Ins2+/− mice. However, these differences were
only evident for a brief period (Fig. 2b, d), suggesting that there
were no lasting negative repercussions in Ins1−/−:Ins2+/− mice.
There were only minor long-term HFD effects on glucose ho-
meostasis (Fig. 2b). Moderate glucose intolerance in the HFD
groups was associated with significant insulin resistance, with
a notable decline at 26 weeks and beyond in HFD-fed vs CD-
fed mice (Fig. 2c). By 16 weeks, all HFD-fed mice had elevat-
ed fasting blood glucose, compared with CD-fed mice
(Fig. 2d). Therefore, any differences between HFD-fed
Ins1−/−:Ins2+/− and Ins1−/−:Ins2+/+ female mice would likely
be driven by attenuated hyperinsulinaemia in young
Ins1−/−:Ins2+/− mice, rather than altered glucose homeostasis.
Lasting protection against obesity in HFD-fed
Ins1−/−:Ins2+/− mice Next, we tested our primary hypothesis
that reduced insulin levels early in life might attenuate diet-
induced obesity. No significant mass differences were observed
between Ins1−/−:Ins2+/− and Ins1−/−:Ins2+/+ pups prior to
weaning (Fig. 3a). However, weight differences between high
fat-fed Ins1−/−:Ins2+/− and Ins1−/−:Ins2+/+ littermates were ap-
parent almost immediately after introduction of the HFD
(Fig. 3a).While HFD-fed Ins1−/−:Ins2+/+ mice were significant-
ly heavier than CD-fed Ins1−/−:Ins2+/+ littermates as early as
18 weeks, the HFD had no detectable effect on Ins1−/−:Ins2+/−
body mass until after 32 weeks (Fig. 3a). Furthermore, on the
HFD, the Ins1−/−:Ins2+/− mice were still significantly lighter
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than their Ins1−/−:Ins2+/+ littermates past 1 year of age (Fig. 3a),
a time when fasting insulin levels were equivalent (Fig. 1i). At
all time points studied, the HFD increased absolute fat mass
(Fig. 3b) and proportional fat mass (data not shown) in
Ins1−/−:Ins2+/+ mice. Moreover, HFD-fed Ins1−/−:Ins2+/− mice
showed a significant attenuation of adipose tissue expansion
when compared with Ins1−/−:Ins2+/+ mice (Fig. 3b). These data
demonstrate that lower circulating insulin in young Ins1−/−:Ins2+/−
mice corresponded with a delayed and reduced degree of
HFD-induced weight gain and obesity.
To look for evidence of adipose programming underlying
differences in obesity, we examined inguinal (subcutaneous)
and gonadal (visceral) WAT depots in 25-week-old mice. In
gonadal WAT, perilipin staining revealed that while all HFD-
fed mice had relatively fewer small lipid droplets and more
large lipid droplets than CD-fed mice, Ins1−/−:Ins2+/+ mice
tended to have a greater proportion of the largest lipid droplets
(Fig. 3c, d). However, there were no significant differences
detected in transcript levels of measured WAT adipogenic,
lipogenic or lipolytic genes at this age (Fig. 3e, f).
Effects of HFD on circulating lipids and metabolic factors
To further characterise the effects of lower insulin levels and
attenuated obesity in HFD-fed Ins1−/−:Ins2+/− mice, we mea-
sured lipids and metabolic factors in plasma from fasted
40-week-old mice. All HFD-fed mice had higher cholesterol
and NEFA than CD-fed mice, but triacylglycerols were not
significantly different (Fig. 4a–c). As expected based on body
composition, only Ins1−/−:Ins2+/+ mice showed elevated leptin
on HFD when compared with their chow-fed controls




(n=17–21) (a), blood glucose
responses to intraperitoneal
glucose (n=29–34) (b) and
insulin analogue (n=29–34) (c)
are shown, together with AUC or
area over curve (AOC) (insets,
y-axis units, pmol/l×min [a],
mmol/l×min [b] and %×min [c])
and fasted blood glucose
(n=15–18, most time points) (d).
Dark blue, CD-fed Ins1−/−:Ins2+/+
mice; dark purple, HFD-fed
Ins1−/−:Ins2+/+ mice; light blue,
CD-fed Ins1−/−:Ins2+/−mice; light
purple, HFD-fed Ins1−/−:Ins2+/−
mice. Data are means±SEM.
*p≤0.05, CD vs HFD; †p≤0.05,
Ins1−/−:Ins2+/+ vs Ins1−/−:Ins2+/−
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(Fig. 4d). However, both groups of HFD-fed mice had in-
creased resistin levels (Fig. 4e). We did not detect significant
differences in interleukin 6 (Fig. 4f). GIP levels were simi-
larly elevated in all HFD-fed mice (Fig. 4g). No significant
differences were detected in concentrations of peptide YY
(Fig. 4h) or glucagon (Fig. 4i). Therefore, while adult
Ins1−/−:Ins2+/− mice had attenuated HFD-induced weight
gain and adiposity (Fig. 3), they showed many similarities to
HFD-fed Ins1−/−:Ins2+/+ mice with respect to circulating met-
abolic factors, except leptin. These observations support the
concept that attenuated obesity in Ins1−/−:Ins2+/− mice was
due to the transient reduction of insulin, rather than other
factors.
Energy homeostasis in youngmiceWe examined the energy
balance of HFD-fed Ins1−/−:Ins2+/− and Ins1−/−:Ins2+/+ litter-
mates at 17 weeks, during their growth divergence. Trends
suggested that Ins1−/−:Ins2+/− mice were more active than
Ins1−/−:Ins2+/+ mice in the early hours of the dark cycle
(Fig. 5a). While there were no significant differences in food
intake or respiratory exchange ratios (Fig. 5b, c),
Ins1−/−:Ins2+/− mice exhibited reduced energy expenditure
when compared with Ins1−/−:Ins2+/+ littermates (Fig. 5d).
Ins1−/−:Ins2+/− mice also had significantly reduced BAT mass
compared with Ins1−/−:Ins2+/+ littermates at 25 weeks
(p<0.05, Fig. 5e; p=0.102 when normalised to body mass,
Fig. 5f), and lower BAT Cebpa expression (Fig. 5g). Overall,
Perilipin
DAPI
Ins1-/-:Ins2+/+ CD Ins1-/-:Ins2+/- CD
Ins1-/-:Ins2+/+ HFD Ins1-/-:Ins2+/- HFD
Fig. 3 Attenuated obesity in
HFD-fed Ins1−/−:Ins2+/− mice.
(a) Body mass was tracked in
pups (n=19–29, inset) and
weaned mice (n=29–33, most
time points). (b) DEXA-
measured fat mass is shown
(n=8–11). (c, d) Staining
(magnification ×50) for perilipin
(yellow) and DAPI (blue) in
gonadal WAT of 25-week-old
mice (c) is quantified (n=3) in
(d) as frequency per size category.
(e, f) Gene expression in gonadal
(e) and inguinal (f) WAT mRNA
is corrected against Hprt and
normalised to CD-fed
Ins1−/−:Ins2+/+ mice. Dark blue,
CD-fed Ins1−/−:Ins2+/+ mice; dark
purple, HFD-fed Ins1−/−:Ins2+/+
mice; light blue, CD-fed
Ins1−/−:Ins2+/− mice; light purple,
HFD-fed Ins1−/−:Ins2+/− mice.
Data are means±SEM. *p≤0.05,
(*)p=0.051, CD vs HFD;
†p≤0.05, (†)p=0.054, Ins1−/−:
Ins2+/+ vs Ins1−/−:Ins2+/−; *+/+p≤






Diabetologia (2015) 58:2392–2402 2397
Fig. 4 Plasma lipids and
metabolic factors. Fasted levels of
cholesterol (a), triacylglycerols
(b), NEFA (c), leptin (d), resistin
(e), interleukin 6 (f), GIP (g),
peptide YY (h) and glucagon (i)
in 40-week-old mice (n=8–12).
Dark blue, CD-fed Ins1−/−:Ins2+/+
mice; dark purple, HFD-fed
Ins1−/−:Ins2+/+ mice; light blue,
CD-fed Ins1−/−:Ins2+/−mice; light
purple, HFD-fed Ins1−/−:Ins2+/−
mice. Data are means±SEM.
*p≤0.05, CD vs HFD; *+/+p≤
0.05, CD-fed vs HFD-fed
Ins1−/−:Ins2+/+ mice; †HFDp≤
0.05, HFD-fed Ins1−/−:Ins2+/+ vs
Ins1−/−:Ins2+/− mice
Fig. 5 Energy homeostasis and brown adipose tissue. (a–d) In HFD-fed
17-week-old mice (n=6–8), 24 h activity (a), food intake (b), respiratory
exchange ratio (c) and energy expenditure (d) were averaged across
48–84 h; the dark period is shown in grey. (e, f) In 25-week-old mice
(n=5–7), BAT depot mass is shown as absolute values (e) and propor-
tional to body mass (f). (g) mRNA levels of genes expressed in BAT are
corrected against Tbp and normalised to levels in CD-fed Ins1−/−:Ins2+/+
mice. Dark blue, CD-fed Ins1−/−:Ins2+/+ mice; dark purple, HFD-fed
Ins1−/−:Ins2+/+ mice; light blue, CD-fed Ins1−/−:Ins2+/−mice; light purple,
HFD-fed Ins1−/−:Ins2+/−mice. Energy expenditure is shown as estimated
marginal means±SEM, adjusted for covariates of lean and fat mass; other
data are simple means±SEM. *p≤0.05, CD vs HFD; †p≤0.05,
Ins1−/−:Ins2+/+ vs Ins1−/−:Ins2+/−
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attenuated adiposity in HFD-fed Ins1−/−:Ins2+/− mice was
achieved despite decreased energy expenditure and BAT
mass.
Long-term effects of short-term INSULIN2 treatment In a
small experiment designed to independently assess the effect
of elevated insulin levels during growth, HFD-fed 17-week-
old mice were implanted with mini osmotic pumps secreting
murine INSULIN2 or vehicle (control) for 4 weeks.
INSULIN2-treated Ins1−/−:Ins2+/− mice tended to reach
fasting insulin levels similar to those of Ins1−/−:Ins2+/+ mice
during the treatment, without immediate effects on body mass
(Fig. 6a, b). However, by 1 year of age, Ins1−/−:Ins2+/− mice
that had been previously INSULIN2-treated tended to have
body and WAT masses that were intermediate between
vehicle-treated Ins1−/−:Ins2+/− and Ins1−/−:Ins2+/+ mice
(Fig. 6b, c). Regardless of INSULIN2 treatment status, all
HFD-fed Ins1−/−:Ins2+/− mice tended to exhibit relatively
smaller lipid droplets than Ins1−/−:Ins2+/+ mice in gonadal
WAT, with modest trends to suggest that INSULIN2 treatment
may be associated with more of the largest droplets (Fig. 6d,
e). Compared with the other groups, vehicle-treated
Ins1−/−:Ins2+/− mice tended to have higher transcript levels
of genes associated with fatty acid uptake and lipogenesis in
gonadal WAT (e.g. p=0.058 for Lpl; Fig. 6f) and had lower
inguinal WAT Cebpb mRNA than other groups (Fig. 6g).
INSULIN2 treatment tended to be associated with increased
BAT Prdm16 expression (Fig. 6h). While this experiment did
not definitively show that short-term INSULIN2 treatment
was sufficient to promote obesity in Ins1−/−:Ins2+/− mice, it






Fig. 6 Long-term effects of HFD
and INSULIN2. Mice were
implanted with pumps releasing
INSULIN2 or vehicle for 4 weeks
(indicated by grey hatching).
(a) Fasted insulin levels, n=3.
(b) Body mass, n=3. (c–e)
At 50 weeks, characterisation
included WAT depot weight
proportional to body mass (c) and
gonadal WAT staining
(magnification ×50) for perilipin
(yellow) and DAPI (blue) (d)
(n=3; quantification is shown in
e as frequency per size category).
(f–h) mRNA levels of genes
expressed in gonadal WAT
(f), inguinal WAT (g) and BAT
(h) are corrected against Tbp or
Hprt, and normalised to levels in
Ins1−/−:Ins2+/+ mice. Dark purple,
vehicle-treated Ins1−/−:Ins2+/+
mice; light purple, vehicle-treated
Ins1−/−:Ins2+/−mice; hatched bars
and triangles, INSULIN2-treated
Ins1−/−:Ins2+/− mice. Data are
means±SEM. ‡p≤0.05, for the
indicated comparisons;
(‡)p=0.058 in (f) for group effect;
and (‡)p≤0.057 in (h) for the
indicated comparisons
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Discussion
Our objective was to test the hypothesis that reducing insulin
secretion by partial disruption of the Ins2 gene would prevent
diet-induced obesity. A transient attenuation of insulin hyper-
secretion in young, growing Ins1−/−:Ins2+/− mice allowed us
to test the secondary hypothesis that these anti-obesity effects
would persist despite late-onset HFD-induced elevations in
insulin. Our data indicate that, under these experimental con-
ditions, reduced dosage of the ancestral Ins2 gene can provide
protection against obesity similar to that gained by reducing
the dosage of rodent-specific Ins1 [11]. Importantly, the cur-
rent study also identified the growth period of adolescence and
young adulthood as a potentially critical time to suppress in-
sulin escalation.
It is an intriguing concept that there could be key interven-
tional periods for influencing obesity and associated health
risks [34]. In humans, the rate of BMI increase during pubes-
cence and the maximum BMI during young adulthood
(22–24 years) can both be stronger predictors of adiposity at
mature adulthood (35–45 years) than adult lifestyle variables
[35]. It has previously been shown that early-life manipula-
tions, such as short-term insulin treatment in neonatal rats,
leads to increased weight gain as well as impaired glucose
tolerance and insulin responsiveness into adulthood [36].
Our experiments with short-term INSULIN2 treatment in
Ins1−/−:Ins2+/−mice also pointed to possible long-term effects
on weight gain, although the limited period of insulin treat-
ment could have led to impaired insulin sensitivity and a last-
ing elevation of insulin secretion, as previously seen [36].
Collectively, our investigation indicates that repression of
hyperinsulinaemia in young, HFD-fedmice can attenuate obe-
sity throughout adulthood.
Tissue analyses showed subtle dissimilarities in lipid drop-
let size distributions between Ins1− /− :Ins2+/− and
Ins1−/−:Ins2+/+ mice in the gonadal WAT at 25 weeks, imply-
ing possible divergence in adipocyte hypertrophy or hyperpla-
sia, although no significant transcriptional changes were de-
tected. By the age of 50 weeks, HFD-fed Ins1−/−:Ins2+/− mice
showed a tendency for increased expression of genes associ-
ated with fatty acid uptake and lipogenesis in gonadal WAT.
This could indicate continued maintenance of adipocyte func-
tion and energy storage capacity, suggested to be metabolical-
ly beneficial in both humans and mice [37–40], and it may
have been counteracted by exogenous INSULIN2 treatment.
Interestingly, we did not detect elevated adiposeUcp1 expres-
sion in Ins1−/−:Ins2+/− female mice, unlike Ins1+/−:Ins2−/−
HFD-fed male mice [11]. Rather, interscapular depots of
BAT were smaller in young Ins1−/−:Ins2+/− female mice than
in Ins1−/−:Ins2+/+ littermates, similar to the effect of knocking
the insulin receptor out of BAT [41], and this may have con-
tributed to the lower energy expenditure. Another caveat com-
plicating the energy expenditure interpretation is that there
were differences in body composition [42], and human studies
have also shown that obese individuals may not show reduced
total energy expenditure even if they are less active than lean
individuals [43, 44]. Therefore, adipose-level changes distinct
from those outlined in our previous study [11] may have con-
tributed to attenuated adiposity in the HFD-fed Ins1−/−:Ins2+/−
female mice.
The HFD-fed Ins1−/−:Ins2+/− female mice maintained
protection against obesity into adulthood, despite the fact
that their suppression of fasting insulin had reverted by
1 year. At 50 weeks of age, the islet Ins2 mRNA and
insulin levels of HFD-fed Ins1−/−:Ins2+/− mice approached
those of Ins1−/−:Ins2+/+ littermates. Although we could not
elucidate the chronology of the relationship between this
late-onset hyperinsulinaemia and insulin resistance, it is
clear from our results that reducing adipose tissue expan-
sion and weight gain cannot always prevent the decline in
glucose tolerance and insulin sensitivity that is associated
with high-fat feeding.
In conclusion, results from this investigation support the
body of literature that places hyperinsulinaemia mechanisti-
cally upstream of diet-induced obesity. The growth period of
adolescence and young adulthood may be a critical time for
shaping future adiposity and our study demonstrates that, in
mice, repression of insulin hypersecretion during this life
stage can provide long-term protection against obesity.
Interestingly, pubescence in humans is associated with a tran-
sient period of reduced blood glucose responsiveness to insu-
lin, and elevated insulin secretion [45, 46]. It could be worth-
while to explore whether limiting insulin hypersecretion
during this phase could have lasting anti-obesity effects
in humans.
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